-
Razionale scientifico
The "Summer School of Immuno-Oncology: Emerging targets and combination therapies" aims to discuss knowledge and recent advances in the field of cancer immunotherapy. A panel of national and international lecturers will cover various aspects of preclinical and clinical immuno-oncology, ranging from the study of basic pathogenetic mechanisms for the discovery of new immunotherapeutic targets to more clinical aspects related to the effectiveness of combinatorial approaches in boosting cancer immunotherapy. The school will provide young oncologists, PhDs and PhD students, involved in clinical and research projects related to cancer immunotherapy, with a solid background in novel immuno-oncology topics. In particular, we will focus on issues related to: inflammation and cancer; the immunity-cancer interface: mutational load of the tumor and editing of immune responses; myelopoietic alterations, tumor microenvironment and anticancer immunotherapy; radioimmunotherapy and immunotherapy of blood cancers; clinical immunotherapy; antiviral response of the host and cancer development; role of immunosenescence and inflammaging in neoplasms; and immunological disorders and cancer. Furthermore, advanced knowledge on statistics will be provided for the analysis of preclinical and clinical data. The goal is to discuss the current state of knowledge in the field of cancer immunotherapy from an interdisciplinary and translational “bench-to-bedside” standpoint.
The official language of the course is English. No simultaneous translation will be provided.
-
Modalità di partecipazione
Per garantire il rispetto delle disposizioni sanitarie in materia di Covid 19, questo evento si svolgerà in forma ibrida. Sarà possibile seguire l’attività formativa in presenza presso la sede congressuale (Corso Residenziale) o in remoto (Evento Digitale).
ATTENZIONE! Per la partecipazione in presenza è necessario un GREEN PASS in corso di validità.
I due pulsanti sottostanti permettono di iscriversi secondo la modalità desiderata, fino ad esaurimento dei posti disponibili. L’iscrizione all’attività potrà avvenire esclusivamente attraverso procedura online, non saranno accettati nuovi iscritti presso la sede congressuale.
Posti terminati per il Corso Residenziale.
Vai al Corso Residenziale
Iscrizioni ancora aperte per l'Evento Digitale.
AccMed si riserva di realizzare l’evento esclusivamente in modalità digitale qualora la situazione dell’emergenza sanitaria da Covid-19 lo rendesse necessario. In tal caso, sarà cura di AccMed informare docenti e iscritti della variazione nella modalità di fruizione dell’evento.
I partecipanti che seguiranno l'attività in remoto avranno bisogno di una connessione internet di buona qualità e di un dispositivo (PC, Smartphone, Tablet) con browser Internet recente (es. qualsiasi versione aggiornata di Chrome o Firefox).
-
Programma dell’attività formativa
Monday, 30th August
10.00 - Registration and welcome coffee
10.30 - Opening Address (Gian Carlo Avanzi, Marco Krengli)
11.00 - Introduction to the school and programme presentation (Marisa Gariglio, Alessandra Gennari, Antonio Sica)
11.30 - Opening Lecture: Cancer and Inflammation (Alberto Mantovani) Chairmen: Gian Carlo Avanzi, Antonio Sica
12.30 - Lunch break
AFTERNOON SESSION: The cancer-immune system interface
Chairmen: Gianluca Aimaretti, Ciro Isidoro14.00 - Tumor mutational load and cancer therapy (Giovanni Germano)
14.45 Targeting adaptive immunity in cancer (Enrico Lugli)
15.30 - Coffee break
16.00 - Professional antigen presenting cells/DC in cancer (Silvano Sozzani)
16.45 - Immune checkpoints in cancer therapy (Andrea Anichini)
17.30 - Discussion
Facilitator: Antonio Sica18.00 - Adjourn
Tuesday, 31st AugustMORNING SESSION: Anticancer immunotherapies: pros and cons
Chairmen: Umberto Dianzani, Antonia Follenzi8.40 - Lecture: Update on anticancer immunotherapies
Paolo Antonio Ascierto9.40 - Extracellular Matrix at the cross-road between cancer and immunity (Mario Colombo)
10.00 - Tumor microenvironment and emergency hematopoiesis (Laura Strauss)
10.30 - Coffee Break
11.00 - Suppressor myeloid cells in cancer (Vincenzo Bronte(
11.30 - NK in cancer therapy (Angela Santoni)
12.00 - Discussione Q&A
Facilitator: Gianluca Gaidano12.30 - Giovanni Melillo interviewed by Pier Luigi Canonico (NO CME)
13.00 - Lunch Break
AFTERNOON SESSION: Hemato & Radio Immunotherapy
Chairmen: Marco Krengli, Andrea Riccardo Filippi14.30 - Radiotherapy and immunotherapy: current knowledge of a clinical partnership (Pierfrancesco Franco)
15.00 - Radiotherapy effects on tumor micro-environment (Andrea Riccardo Filippi)
15.30 - SBRT and immunotherapy, a winning partnership? (Davide Franceschini)
15.50 - Coffee Break
AFTERNOON SESSION: Hemato & Radio Immunotherapy
Chairmen: Gianluca Gaidano, Giovanni Martinelli16.20 - Molecular determinants of immune-response (Massimo Dominici)
16.40 - Immune checkpoints inhibitors in liquid tumors (Gianluca Gaidano)
17.10 - CAR-T cells (Marco Ladetto)
17.30 - Discussion Q&A
Facilitator: Giovanni Martinelli18.15 - CME Session Adjourn
18.30 - Cocktail with the statisticians – (NO CME)
Chairmen: Paolo Bruzzi, Fabrizio Faggiano, Giovanni MelilloMethodological challenges in Phase I Immuno Clinical Trials (Giovanni Melillo) (15 min)
Innovative trial design – Adaptive Immunotherapy Trials Oriana Nanni, Valter Torri (15 min)
Endpoints & Summary Indicators in Immunotherapy Trials Paolo Bruzzi (15 min)
Wednesday, 1st SeptemberMORNING SESSION: Immunotherapy in the Clinic
Chairmen: Pier Luigi Canonico, Alessandra Gennari9.00 - Lecture: Regulatory Process and clinical benefit (Armando Genazzani)
9.40 - IO & Lung Cancer (Silvia Novello)
10.00 - IO & Urology (Matteo Bellone)
10.20 - Immunotherapy of Melanoma: what we already know and future perspectives (Michele Del Vecchio)
10.40 - Coffee Break
11.00 - Breast Cancer: evolution of innovative agents from CDK 4/6 to checkpoint inhibitors (Valentina Guarneri)
11.20 - IO & Hepatocellular carcinoma (David J. Pinato)
11.40 - Innovative IO therapies in solid tumors: CAR-T, oncolytic viruses and beyond (Giuseppe Curigliano)
12.15 - Antiandrogenic therapy in prostate cancer and COVID (Andrea Alimonti)
12.30 - Discussion Q&A
Facilitator: Alessandra Gennari13.00 - Lunch Break
AFTERNOON SESSION: The complex interplay between SARS-CoV-2 and the host immune response
Chairmen: Marisa Gariglio, Santo Landolfo14.30 - Vaccines and monoclonals to regain our freedom (Rino Rappuoli)
15.10 - SARS COV2 variants (Nicole Fischer)
15.50 - Innate RNA sensing of SARS-CoV2 and strategies of viral evasion (John Hiscott)
16.30 - Coffee Break
17.00 - The cGAS-STING pathway in COVID-19 – protective and pathogenic potential (Soren Paludan)
17.40 - Discussion Q&A
Facilitator: Marco De Andrea18.00 - Adjourn
Thursday, 2nd SeptemberMORNING SESSION: Immunosenescence, Inflammaging and Cancer
Chairmen: Lia Rimondini, Annalisa Chiocchetti9.00 - Inflammaging and Cancer (Massimiliano Bonafè)
9.50 - Common mechanisms of age-related diseases: implication for disease-specific biomarkers identification (Fabiola Olivieri)
10.40 - Coffee Break
11.10 - Genetics and Epigenetics of Aging (Paolo Garagnani)
12.00 - Discussion Q&A
Facilitator: Ciro Isidoro12.30 - Lunch Break
AFTERNOON SESSION: Immunological disorders and cancer prognosis and therapy
Chairmen: Claudio Santoro, Mario Pirisi14.00 - Allergy/autoimmunity and cancer (Marinos Kallikourdis)
14.50 - Microbioma, immunity and cancer (Maria Rescigno)
15.10 - Tertiary lymphoid structures in immunology and immunotherapy (Catherine Fridman)
15.30 - Discussion Q&A
Facilitator: Antonio Sica16.00 - Closing Lecture: B cells and antibodies, the next challenge in immunotherapy (Wolf Fridman)
16.30 - Adjournment and final evaluation questionnaire (Marisa Gariglio, Alessandra Gennari, Antonio Sica)
[Download program]